Prof. Paula Hammond speaks with MSNBC’s Andrea Mitchell about why she feels it's imperative that researchers from different disciplines collaborate on cancer research. Hammond explained funding is needed to bring “scientists, clinicians, technologists together in places like the Koch Institute," where people "work collectively toward a cure.”
In an interview with the BBC, Prof. Heidi Williams argues that there should be more incentives for developing cancer prevention techniques and treatments for early-stage cancers. "If you look at drugs that get approved by the FDA, they all tend to be for very late stage cancer patients,” says Williams.
Prof. Phillip Sharp co-authored this piece for Huffington Post about VP Joe Biden’s national cancer research initiative. “The most important thing about collaboration is that it unquestionably saves lives.”
Prof. Paula Hammond speaks with Tom Ashbrook of NPR’s On Point about Vice President Biden’s new cancer initiative. Hammond likens the challenge to “going to the moon and back, it’s creating a permanent space station out there as well that allows us to continue to learn about some of the new approaches.”
Prof. Michael Yaffe speaks with Scott Kirsner of WBUR’s Radio Boston about Vice President Joe Biden’s new cancer initiative. Prof. Yaffe says that the announcement comes at a “golden era for cancer research. We’ve laid the groundwork and we’re poised with incredible technologies, knowledge and understanding of the disease.”
In an article for The Hill, Prof. Phillip Sharp writes about the need for increased funding for cancer research. “Our arsenal against cancer is growing, and more discoveries and therapies are in the pipeline—but these will only be realized if we sustain our efforts,” Sharp writes.
In an article for U.S News & World Report, Alan Mozes writes that MIT researchers have developed a new imaging technique that lights up cancer cells. The technique may “eventually help surgeons remove all of a cancer the first time.”
Researchers from MIT, Duke University Medical Center and Massachusetts General Hospital have developed a technique for lighting up cancer cells, reports Alice Park for TIME. The technique could “help doctors to target radiation therapy to just the right parts of a tumor to kill remaining cancer cells.”
MIT researchers have found that few incentives exist to encourage research on disease prevention, reports Austin Frakt for The New York Times. “R & D on cancer prevention and treatment of early-stage cancer is very socially valuable,” Profs. Heidi Williams and Ben Roin explain, “yet our work shows that society provides private firms…surprisingly few incentives.”
In an article for Stat, Andrew Joseph writes that the Commonwealth Foundation for Cancer Research is committing $20 million to the Bridge Project, which funds research at the Koch Institute and Dana-Farber. “We’re looking for the best people, regardless of where they are, to tackle these very important problems,” explains Tyler Jacks, director of the Koch Institute.
In a new paper, Prof. Andrew Lo argues that the FDA should apply less stringent criteria when approving experimental drugs for terminal diseases that have few treatment options, writes Ed Silverman for The Boston Globe. “For terminal patients with no existing treatments, it seems to make sense to be more lenient,” says Lo.
Prof. Robert Horvitz speaks with Bloomberg TV’s Caroline Hyde about new developments in creating more effective treatments for cancer. Horvitz explains that “biologists have figured out what it is that keeps the immune system from, in general, attacking cancer cells and have learned to unleash that innate ability and attack a cancer in a patient.”
A team led by Prof. Michael Cima is developing an implantable sensor that can monitor a tumor’s response to cancer drugs, writes Eric Levenson for Boston.com. “The sensor would function like a long-term medical biopsy, giving doctors a continuous look at how a tumor is developing,” Levenson explains.
Jamie Ducharme writes for Boston Magazine that MIT researchers are developing a biochemical sensor that could provide updates on cancerous tumors. The sensor “could be implanted in cancerous tissue during a patient’s first biopsy. After that, it would stay in the tissue and transmit data about the state of the tumor to an external device.”
A new study on cancer drug development by MIT researchers found that pharmaceutical firms overlook drugs for early-stage tumors, writes Jordan Graham for The Boston Herald. “There’s dramatically more investments in the late-stage treatments,” says Prof. Benjamin Roin.